HelenMaMD

Hematologic Oncology

Assistant Professor, Attending Physician

Dr. Ma is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Helen Ma is a hematologist and oncologist in Long Beach, CA and is affiliated with VA Long Beach and University of California Irvine. She specializes in hematologic oncology and is experienced hematology and oncology.

New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 2017 - 2020
NYU Grossman School of MedicineResidency, Internal Medicine, 2014 - 2017
Geisel School of Medicine at DartmouthClass of 2014

PubMed

32 citations
First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.
Jennifer E Amengual, Jennifer K. Lue, Helen Ma, Renee Lichtenstein, Bijal D. Shah
The Oncologist. 2021-03-01
25 citations
T-cell lymphomas, a challenging disease: types, treatments, and future
Helen Ma, Maher Abdul-Hay
International Journal of Clinical Oncology. 2017-02-01
92 citations
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Lorenzo Falchi, Helen Ma, Sandra Klein, Jennifer K. Lue, Francesca Montanari
Blood. 2020-11-10

Abstracts/Posters

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)
Helen Ma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Survival outcomes of patients with peripheral T-cell lymphomas (PTCL) treated with chemotherapy and/or novel agents: The Columbia University experience.
2019 ASCO Annual Meeting - 6/1/2019